We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Switch to CAD Technology Greatly Improves Lab-On-A-Chip Capability

By LabMedica International staff writers
Posted on 12 May 2014
The lab-on-a-chip holds potential for reducing cost of medical diagnostics while expanding access to health care. More...
Now scientists have developed computer aided design (CAD) software to enable far more than one or two tests on a single chip.

In the near future healthcare professionals may be able to routinely run clinical lab tests almost instantly on a digital microfluidic machine about the size of credit card. These lab-on-a-chips (LOCs) would not only be quick—results available in minutes—but also inexpensive and portable. They could be used at point-of-care, and even at long distance from the nearest medical clinic.

But as powerful as they may be, they could be far better, said Shiyan Hu, associate professor of electrical and computer engineering at Michigan Technological University (MTU; Houghton, MI, USA). Current LOCs can generally run no more than a test or two because the chips are designed manually. If the LOCs were made using computer-aided design (CAD), you could run dozens of tests with, for example, a single drop of blood. “In a very short time, you could test for many conditions,” said Prof. Hu; “This really would be an entire lab on a chip.” With PhD student Chen Liao, Prof. Hu has taken the first step. “We have developed software to design the hardware,” he said.

Their work, described in, and featured on the cover of, the March, 2014, edition of the journal IEEE Transactions on Nanobiosciences, focuses on routing a droplet of blood or other fluid through each test on the chip efficiently while avoiding contamination. A key part in LOC CAD is physical-level synthesis. It includes the LOC placement and routing, where placement is to determine the physical location and the starting time of each operation, and routing is to transport each droplet from the source to the destination.

“It has taken us four years to do the software, but to manufacture the LOC would be inexpensive,” said Prof. Hu; “The materials are very cheap, and the results are more accurate than a conventional lab’s.” Prof. Hu plans to fabricate their own biochip using their software.

Related Links:

Michigan Technological University



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.